WuXi STA, a subsidiary of WuXi AppTec, is a leading CRDMO providing integrated CMC services from discovery to commercial manufacturing. WuXi STA now has multiple flow chemistry R&D labs and 25 continuous manufacturing lines in its 3 different API manufacturing sites. The company has supported over 500 continuous manufacturing projects, including more than 20 late-stage and commercial projects.
Asymchem is a leading global Contract Development and Manufacturing Organization (CDMO) offering integrated solutions across all stages of drug development and into commercialization. Through continual investment for more than 10 years, Asymchem has mastered flow chemistry technology for large scale manufacture and registered patents around the world. By combining process optimization, modularization, and automation, our platform can improve the productivity and quality of pharmaceuticals. It has been applied to and improved productivity of multiple key intermediates and API commercial projects all while complying with GMP requirements.
Dec Group is the leading global provider of contained powder handling systems and process containment technologies. It has been supplying the pharmaceutical and chemical industries for more than 35 years. Its subsidiary AWL is at the forefront of the design and manufacture of continuous processing systems and supplying continuous reactors, crystallizers as well as filtration systems and dryers from laboratory to production scale.
“Since 1986 Zeton has been a leader in the design and fabrication of lab scale systems, pilot plants, demonstration plants and small production plants, with a focus on modularity. Customers trust Zeton to help them bring their unique process technologies to the market efficiently and cost effectively. Zeton has completed over 1000 projects in 45 countries. Our team of over 300 dedicated employees operate from state-of-the-art facilities in two countries to serve customers worldwide. Over the years Zeton has developed a niche expertise in designing and building flow chemistry projects.”
PharmaBlock is a global, fully integrated CDMO with FDA inspected GMP manufacturing and over 505 m3 of reactor capacity. PharmaBlock is focused on innovative chemistry and low-carbon manufacturing. The company provides development and manufacturing solutions for pharmaceutical intermediates, drug substances and drug products throughout the development and commercial stages. To further realize safe, efficient, and green manufacturing processes, PharmaBlock has developed an advanced chemistry and engineering technology platform, featuring flow chemistry, micropacked bed hydrogenation, heterogeneous catalysis, biocatalysis, crystal engineering, etc.
Optimal Industrial Technologies
Optimal Industrial Technologies has more than 30 years’ experience in the automation and optimisation of control and data management systems for the pharmaceutical, biotech and life science industries.
Our PAT Knowledge Management software platform, synTQ®, enables real-time process monitoring and the control of critical quality attributes, non-invasively, to facilitate Quality by Design (QbD) via Process Analytical Technology (PAT).
The demands being placed on manufacturers in relation to production costs, product quality and business sustainability are ever increasing. We strive to deliver measurable improvements in these
Pharmaceutical Online provides the pharmaceutical manufacturing and packaging industry with exclusive and actionable information to help industry members tackle the challenge of bringing life-saving and life-improving therapies to market. Our goal is to help industry professionals facilitate connections and gain insight into innovative business strategies, new safety regulations, and technology offerings shaping your daily responsibilities in dosage formulation, facility maintenance, validation, inspection, serialization, risk management, and logistics.
Pharmaceutical Online provides the pharmaceutical manufacturing and packaging industry with exclusive and actionable information to help industry members tackle the challenge of bringing life-saving and life-improving therapies to market.
The audience for this online community is 45,000+ newsletter subscribers.